EasySep™ Human Hematopoietic Progenitor Cell Enrichment Kit II

总览

使用 EasySep™ 人造血祖细胞富集试剂盒 II，通过免疫磁性负选，可轻松高效地从新鲜人脐带血样本中分离高纯度的造血祖细胞。EasySep™ 技术结合单克隆抗体的特异性与无柱磁系统的简便性，已在发表的研究中广泛应用超过 20 年。

在此 EasySep™ 负选过程中，不需要的细胞通过抗体复合物与磁珠标记。以下细胞将被去除：粒细胞、T 细胞、B 细胞、单核细胞、树突状细胞、NK 细胞、红细胞及血小板。使用 EasySep™ 磁极进行无柱分选，带磁性标记的细胞被去除，只需将未标记的造血祖细胞倒入或移取至新的管中即可。分离后的目标细胞可直接用于下游应用，例如流式细胞术、细胞培养、DNA/RNA 提取或小鼠体内移植实验。

了解更多关于 EasySep™ 免疫磁性技术的工作原理，或了解如何使用 RoboSep™ 实现免疫磁性细胞分离的全自动化。探索更多优化实验流程的相关产品，包括培养基、补充物、抗体等。

磁极兼容性
• EasySep™磁极（产品号 #18000）
• “The Big Easy” EasySep™磁极（产品号 #18001）
• RoboSep™-S（产品号 #21000）

分类
细胞分选试剂盒

细胞类型
造血干/祖细胞

种属
人

样本来源
脐带血

分选方法
负选

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
干细胞生物学

查看更多显示更少

实验数据

The content of CD34+ cells before and after the cell isolation procedure are 0.7% and 82.4%, respectively.

Figure 1. EasySep™ Human Progenitor Cell Enrichment Kit II

Starting with 36- to 48-hour-old cord blood, the CD34+ cell content of the isolated fraction is typically 77.5 ± 16.0% (mean ± SD using the silver EasySep™ Magnet). In the above example, using fresh cord blood, the purities of the start and final isolated fractions are 0.7% and 82.4%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

RoboSep™ Human Progenitor Cell Enrichment Kit II

Catalog #

17936RF

Lot #

All

Language

English

Document Type

Product Information Sheet

Product Name

EasySep™ Human Progenitor Cell Enrichment Kit II

Catalog #

17936

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

RoboSep™ Human Progenitor Cell Enrichment Kit II

Catalog #

17936RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

RoboSep™ Human Progenitor Cell Enrichment Kit II

Catalog #

17936RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

RoboSep™ Human Progenitor Cell Enrichment Kit II

Catalog #

17936RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human Progenitor Cell Enrichment Kit II

Catalog #

17936

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human Progenitor Cell Enrichment Kit II

Catalog #

17936

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for Hematopoietic Stem and Progenitor Cell Research

Cell Sourcing and Isolation

Expansion and Differentiation

Analysis

相关材料与文献

Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15. N. Tsuji et al. Leukemia 2022 jun

Abstract

To determine whether antigen presentation by HLA-DR on hematopoietic stem progenitor cells (HSPCs) is involved in the development of acquired aplastic anemia (AA), we studied the HLA-DR expression on CD45dimCD34+CD38+ cells in the peripheral blood of 61 AA patients including 23 patients possessing HLA-class I allele-lacking (HLA-class I[-]) leukocytes. HLA-DR-lacking (DR[-]) cells accounted for 13.0-57.1% of the total HSPCs in seven (11.5%) patients with HLA-DR15 who did not possess HLA-class I(-) leukocytes. The incubation of sorted DR(-) HSPCs in the presence of IFN-$\gamma$ for 72??h resulted in the full restoration of the DR expression. A comparison of the transcriptome profile between DR(-) and DR(+) HSPCs revealed the lower expression of immune response-related genes including co-stimulatory molecules (e.g., CD48, CD74, and CD86) in DR(-) cells, which was not evident in HLA-class I(-) HSPCs. DR(-) cells were exclusively detected in GPI(+) HSPCs in four patients whose HSPCs could be analyzed separately for GPI(+) and GPI(-) HSPCs. These findings suggest that CD4+ T cells specific to antigens presented by HLA-DR15 on HSPCs may contribute to the development of AA as well as the immune escape of GPI(-) HSPCs in a distinct way from CD8+ T cells recognizing HLA-class I-restricted antigens.

View publication

MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus. E. Bulaeva et al. Blood 2020 jun

Abstract

Hematopoietic clones with leukemogenic mutations arise in healthy people as they age, but progression to acute myeloid leukemia (AML) is rare. Recent evidence suggests that the microenvironment may play an important role in modulating human AML population dynamics. To investigate this concept further, we examined the combined and separate effects of an oncogene (c-MYC) and exposure to IL3, GM-CSF and SCF on the experimental genesis of a human AML in xenografted immunodeficient mice. Initial experiments showed that normal human CD34+ blood cells transduced with a lentiviral MYC vector and then transplanted into immunodeficient mice produced a hierarchically organized, rapidly fatal and serially transplantable blast population, phenotypically and transcriptionally similar to human AML cells, but only in mice producing IL3, GM-CSF and SCF transgenically, or in regular mice in which the cells were exposed to IL3 or GM-CSF delivered using a co-transduction strategy. In their absence, the MYC+ human cells produced a normal repertoire of lymphoid and myeloid progeny in transplanted mice for many months but, upon transfer to secondary mice producing the human cytokines, the MYC+ cells rapidly generated AML. Indistinguishable diseases were also obtained efficiently from both primitive (CD34+CD38-) and late (GMPs) cells. These findings underscore the critical role that these cytokines can play in activating a malignant state in normally differentiating human hematopoietic cells in which MYC expression has been deregulated. They also introduce a robust experimental model of human leukemogenesis to further elucidate key mechanisms involved and test strategies to suppress them.

View publication

The miR-185/PAK6 Axis Predicts Therapy Response and Regulates Survival of Drug-Resistant Leukemic Stem Cells in CML. H. Lin et al. Blood 2020 apr

Abstract

Overcoming drug resistance and targeting cancer stem cells remain challenges for curative cancer treatment. To investigate the role of miRNAs in regulating drug resistance and leukemic stem cell (LSCs) fate, we performed global transcriptome profiling in treatment-na{\{i}}ve chronic myeloid leukemia (CML) stem/progenitor cells and identified that miR-185 levels anticipate their response to ABL tyrosine kinase inhibitors (TKIs). miR-185 functions as a tumor suppressor; its restored expression impaired survival of drug-resistant cells sensitized them to TKIs in vitro and markedly eliminated long-term repopulating LSCs and infiltrating blast cells conferring a survival advantage in pre-clinical xenotransplantation models. Integrative analysis with mRNA profiles uncovered PAK6 as a crucial target of miR-185 and pharmacological inhibition of PAK6 perturbed the RAS/MAPK pathway and mitochondrial activity sensitizing therapy-resistant cells to TKIs. Thus miR-185 presents as a potential predictive biomarker and dual targeting of miR-185-mediated PAK6 activity and BCR-ABL may provide a valuable strategy for overcoming drug resistance in patients."

View publication

View All Publications

物种	人类
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000)
样本来源	脐带血
Selection Method	Negative

EasySep™人祖细胞富集试剂盒II

产品号 #17936

产品号 #17936RF

产品号 #（选择产品）

产品号 #17936_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

EasySep™人祖细胞富集试剂盒II

产品号 #17936

产品号 #17936RF

产品号 #（选择产品）

产品号 #17936_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (7)

文献 (3)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台